A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

Inclusion Criteria: * Participants with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity * History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * HbA1c ≥ 48 mmol/mol (6.5%), measured by the central laboratory at screening * Known history of Type 1 or Type 2 diabetes mellitus * Current or previous treatment with petrelintide or any other amylin analog